User Fee Discussions Include Funding Parts Of FDA Regulatory Science Plan
Executive SummaryCommissioner Margaret Hamburg’s plans to improve regulatory science at FDA could benefit from application user fees, based on PDUFA negotiations.
You may also be interested in...
List will include whether a designation was lost, but not why, FDA says in final rule clarifying and updated 1992 orphan drug regulations.
As personalized medicine continues to grow, FDA is watching to see if there is a rise in orphan designations for products targeting a “smaller slice” of a common disease.